This Article Full Text Full Text (PDF) All Versions of this Article: biophysj.107.103887v1 93/9/3105    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mattila, J.-P. Articles by Kinnunen, P. K. J. Search for Related Content PubMed PubMed Citation Articles by Mattila, J.-P. Articles by Kinnunen, P. K. J.

Oxidized Phospholipids as Potential Novel Drug Targets

Helsinki Biophysics and Biomembrane Group, Institute of Biomedicine/Medical Biochemistry, FIN-00014, University of Helsinki, Helsinki, Finland

Correspondence: Address reprint requests to Paavo K. J. Kinnunen, Helsinki Biophysics and Biomembrane Group, Institute of Biomedicine/Medical Biochemistry, PO Box 63 (Haartmaninkatu 8), FIN-00014, University of Helsinki, Helsinki, Finland. Fax: 358-0-191-25444; E-mail: paavo.kinnunen{at}helsinki.fi.

The interactions of three therapeutic agents, viz. the antipsychotics HPD and CPZ, and the antineoplastic anthracycline DOX, with oxidatively modified phospholipids were studied by monitoring the quenching of fluorescence of an incorporated pyrene-labeled lipid derivative. All three drugs bound avidly to the two oxidized PCs bearing either an aldehyde or carboxylic function at the end of the sn-2 nonanoyl chain, with the highest affinity measured between CPZ and the latter oxidized lipid. Subsequent dissociation of the above drugs from the oxidized lipids by DNA, acidic phospholipids, and NaCl revealed the binding of these drugs with the aldehyde lipid to be driven by hydrophobicity similarly to their binding to lysophosphatidylcholine, whereas a significant contribution of electrostatics was evident for the lipid with the carboxylic moiety. These results connect to previous experimental data, demonstrating the induction by these drugs of oxidative stress and binding to membrane phospholipids. These issues are elaborated with reference to their clinical use and side effects.